

ERIC M WEXLER M.D., PH.D.



2730 Wilshire Blvd. Suite 325
Santa Monica, CA 90403
ewexler@modernbrains.com
FAX: 1-310-919-1919
TEL: 310-744-5102
www.EricWexlerMD.com

EDUCATION:

2004-2006	University of California Los Angeles. <i>Postdoctoral Fellow</i> ; Neurobehavioral genetics
2002-2004	Stanford University. <i>Postdoctoral Fellow</i> ; Psychopharmacology research, Departments of Psychiatry and Neurosurgery
2003-2004	Palo Alto Veterans Hospital/MIRECC. <i>Postdoctoral Fellow</i> ; Aging-research
1998-2002	Stanford University Medical Center. <i>Resident</i> ; Department of Psychiatry & Behavioral Science, Stanford, CA
1989-1998	Albert Einstein College of Medicine. <i>M.D.</i> , Bronx, NY
1991-1998	Albert Einstein College of Medicine. <i>Ph.D.</i> , Neuroscience, Bronx, NY
1985-1989	Vassar College. <i>A.B.</i> Biochemistry, Poughkeepsie NY

PROFESSIONAL ACTIVITIES (RECENT):

General Adult & Geriatric Outpatient Neuropsychiatry:

2022-Present: **Medical Director** – **PAND Health & California OnTrack**, an expanded coordinated specialty care (CSC+) program providing treatment for first episode psychosis and chronic schizophrenia, and a developer of clinical training materials [See *WSJ* 12/21/2024].

2022-Present: **Consulting Psychiatrist** – **Los Angeles Clippers**

2015-2022: **Medical Director** - **Resilience Treatment Centers**, a CBT/DBT-based comprehensive residential and intensive outpatient program for patients with psychiatric primary diagnoses of Bipolar, Borderline Personality Disorder, Schizophrenia and treatment resistant depression.

2014-present: **Qualified Medical Evaluator** (QME; California) and Independent Medical Evaluator

2012-Present: **Private Practice** - Guided by the principles of evidence-based medicine, I treat a broad range of psychiatric disorders, with substantial clinical experience managing complex neuropsychiatric syndromes, particularly in those individuals with a coexisting neurologic, rheumatologic or medical illness.

2012-Present: **Forensic Consulting Expert** [See section *Recent Cases of Note*, page 8.]

PROFESSIONAL MEMBERSHIPS

2018-2024: **American Neuropsychiatric Association** [*Standards & Ethics Committee, Forensics SIG*]

2019-2024: **American Society of Clinical Psychopharmacology** [*Program Committee, Scientific Reviewer*]

2022-: **Psychiatric Rehabilitation Association** (Academy for Psychiatric Rehabilitation and Recovery)

2004-2024: **American Psychiatric Association**

Past activities (including media):

- Clinical consultant to *Cochrane Reviews* in psychopharmacology of bipolar affective disorder.
- Technical expert on Bipolar disorder and psychosis: *Homeland* (Fox), *Dexter* (Showtime), *etc.*
- Consulting expert on the development of international guideline for the treatment of Huntington's disease, a fatal neurodegenerative condition.

BIOGRAPHY

Dr. Wexler is a recognized expert in psychopharmacology and neuropsychiatry who accepts the most challenging cases of altered mood, impulse control and cognition. For the past two decades he has specialized in caring for the most *treatment-resistant* patients suffering from Bipolar disorder, Schizophrenia and ADHD. He is the founder of Lucidity Behavioral Health and currently serves as the medical director of *California OnTrack*, an intensive coordinated specialty care for adolescents and adults experiencing either first episode or chronic psychosis.

Early in his academic career he graduated Phi Beta Kappa from Vassar College with a degree in biochemistry. During medical school at the Albert Einstein College of Medicine he undertook research into nerve cell development and neurotransmitter function, for which he was awarded both a medical degree (M.D.) and a doctorate in neurobiology (Ph.D.). He next completed his residency in the Department of Psychiatry and Behavioral Science at Stanford University. He received his primary psychotherapy training with Dr. David Burns, best-selling author and the first popularize cognitive-behavioral therapy (CBT) and C. Barr Taylor, author of the APA textbook on evidence-based psychiatry. He then pursued specialized fellowship training in psychopharmacology and neuronal regeneration at Stanford under the auspices of Dr. Alan Schatzberg, former American Psychiatric Association president and coauthor of the official APA textbook of psychopharmacology. During this period, he also served as an attending physician in the emergency department of San Francisco General Hospital/UCSF. He later completed a research fellowship in neurobehavioral genetics at UCLA, before joining the full-time academic faculty at the UCLA David Geffen School of Medicine, in the division of geriatric psychiatry and the center for neurobehavioral genetics. Dr. Wexler subsequently entered private practice, later served as medical director for Resilience Treatment Centers prior to founding Lucidity.

Prior to entering private practice Dr. Wexler, a board-certified psychiatrist and qualified medical examiner, was engaged in both clinic care and basic science research at the UCLA School of Medicine. There his clinical activities included an outpatient clinic that emphasizes mood and impulse control disorders, providing psychiatric consultation for patients with often rare, inherited or autoimmune forms of neurodegeneration. (e.g. patients in the UCLA Huntington's Disease Center of Excellence) and attending on the inpatient geriatric psychiatry unit at the UCLA-Resnick Neuropsychiatric Hospital. Complementing these clinical efforts, his research agenda focused on the following areas: (1) Understanding the molecular mechanisms underlying the effectiveness of common mood stabilizers like lithium. (2) Developing novel experimental models of neuropsychiatric disease (e.g. dementia or autism), primarily using human neural stem cells. (3) Developing and applying novel network ("big data") analytic methods to the problem of understanding the signals that govern early nerve cell development, and how these contribute to brain dysfunction. In addition, he has provided discreet consultation services to individual or organization in the television, print media, legal and investment banking communities.

PAST APPOINTMENTS & CLINICAL ACTIVITIES

Neuropsychiatry & Geriatrics: neurodegeneration specialist

2006-2012 Geriatric Psychiatry Attending, Resnick Neuropsychiatric Hospital, University of California Los Angeles, Los Angeles, CA

2006-2012 Attending psychiatrist for UCLA Huntington's Disease Center of Excellence. Department of Neurology. University of California Los Angeles, Los Angeles, CA

2006-2012 Attending psychiatrist to the Neurogenetics Clinic, Department of Neurology, University of California Los Angeles, Los Angeles, CA

2005-2006 Consult/Liaison Attending psychiatrist to organ transplantation services and general medical services, UCLA Hospital, Los Angeles, CA

Emergency Psychiatry

2002-2004 *Attending Psychiatrist:* Psychiatric Emergency Services, San Francisco General Hospital — University of California: San Francisco

2000-2002 *Psychiatrist:* Schuman-Liles Clinic: Fremont CA

Basic Science: brain development, genomics, psychopharmacology & “big data analysis”

2006-2013 *Assistant Professor:* Semel Institute: Center for Neurobehavioral Genetics and Division of Geriatric Psychiatry, Department of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

General psychiatry

2005-2012 *Attending adult outpatient psychiatry clinic,* Department of Psychiatry and Behavioral Science, University of California Los Angeles, Los Angeles, CA

2004-2006 *Clinical Instructor:* Department of Psychiatry and Behavioral Science, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

PROFESSIONAL CERTIFICATIONS:

1999- California Medical License: #A69685
 1999- DEA License: #BW6493631, XW6493631 (Center for Substance Abuse Treatment)
 2004- Diplomate in Psychiatry: #53505, American Board of Psychiatry & Neurology
 2014- Qualified Medical Examiner; California

AWARDS & HONORS:

<u>Children and Youth Behavioral Health Initiative (\$2,000,000)</u>	2024-2026
CSC for First Episode of Psychosis Implementation Role: Principle Director	
<u>California Institute of Regenerative Medicine (\$16,300)</u>	2011-2014
Regeneration of Functional Human Corneal Epithelial Progenitor Cells Role: Coinvestigator	
<u>J.D.French Foundation for Alzheimer’s Research (\$400,000)</u>	2008-2012
Development of transgenic human neural stem cells as a model of Alzheimers dementia Role: Principle Investigator	
<u>National Institutes of Health NIMH-K08MH74362 (\$776,500)</u>	2006-2011
Role of Wnt Signaling in Adult Hippocampal Progenitor Cell Development Role: Principle Investigator	
<u>National Alliance for Research on Schizophrenia and Depression (\$60,000)</u>	2002-2006
Effects Of Lithium/Wnt on Adult Neural Stem Cells Role: Principle Investigator	

<u>APIRE/Wyeth M.D., Ph.D. Research Award (\$40,000)</u> Effects of Mood Stabilizers in Human Neural Stem Cells Role: Principle Investigator	2002-2004
<u>T32MH019938 Biobehavioral research training grant</u> (Alan Schatzberg M.D. & Theo Palmer Ph.D.); Stanford University Medical Center, Stanford, CA Role: Postdoctoral Fellow	2002-2003
<u>Mental Illness Research, Education and Clinical Center fellowship</u> Sierra Pacific MIRECC (Jerome Yeavage M.D.) Palo Alto Veterans Hospital, Palo Alto, CA Role: Postdoctoral Fellow	2003-2004
<u>T32NS048004 Neurobehavioral genetics training grant</u> Departments of Psychiatry and Neurology (Daniel Geschwind M.D., Ph.D.) University of California Los Angeles, Los Angeles, CA Role: Postdoctoral Fellow	2004-2005
<u>Pfizer-Neuroscience Resident of the Year Award</u>	2002
<u>Medical Scientist Training Program</u>	1993-1997
<u>American Heart Association Fellowship</u>	1991-1992
<u>Phi Beta Kappa</u>	1989
<u>Virginia Swinburn-Brownell Prize in Experimental Biology</u>	1989
<u>Charles Dana Undergraduate Student Research Fellowship</u>	1988
<u>First Place: New York State Team Debate Championship</u>	1985

PRESENTATIONS & TEACHING

Forensic considerations in Functional Neurological Disorder: Controversies at the Intersection of Forensics and Functional Neurological Disorder. Caitlin Adams, Chadrick Lane, Hal Wortzel, Gabriel Ben-Dor, Shafi Lodhi, **Eric Wexler**, David Perez. American Neuropsychiatric Association Annual Meeting 2024

Mental Health in Huntington's Disease: empowering patients and their families. HOPE & COPE: Huntington's Disease Educational Day. Huntington's Disease Center of Excellence at UCLA 2023

Recognizing and treating thought disorders. UCLA-SM Inpatient Social Worker Inservice 2023

UCLA/GLA-VA Psychiatry Residency: Career Opportunities Panel Discussant 2023

Psychosocial rehabilitation for thought disorders: Hired-Power Treatment. 2023

Ketogenic diet in the treatment of major mood disorders. UCLA Psychiatry Journal Club 2023

Thought Leadership Series - Part 1: Understanding Psychosis. Newport Academy 2023

What is Coordinated Specialty Care for Psychosis? Rogers Behavioral Health 2023

Registered postgraduate supervision [2022-present]: Kyle Menschel ACSW, Brittany Neiman ACSW, Natalie Mark AMFT

- Integrated psychosocial interventions for treating psychosis* UCLA Psychiatry Journal Club 2022
- Coordinated intensive outpatient treatment of psychosis.* UCLA Inpatient Social Worker Inservice 2022
- Rescue from Psychosis: Making Recovery a Reality.* Janis Black Warner Speaker Series, NAMI 2022
- Emerging pharmacologic treatments for Schizophrenia* UCLA Psychiatry Journal Club 2021
- rTMS and other adjunctive treatments for negative symptoms in schizophrenia.* UCLA Psychiatry Journal Club 2020
- Recognizing & Treating Schizophrenia.* Psychotherapist Continuing Education Program, RTC 2019
- Registered Postdoctoral Clinical Supervisor [2015-2021] for Cinzia C. Roccaforte, Psy. D., Annie Zadori, PsyD, Anthony Odozi, Ed.D. April Genovese Psy.D. Attending supervision of Oluwafikunmi Sobowale MD, Tark Hadzic MD, PhD
- Cannabis exacerbations of mania and psychosis* UCLA Psychiatry Journal Club 2016
- "After the Love is Gone - Keeping Your Client's Career from Ruin"* Panel Discussion 2013
- Neurogenesis and its role in the etiology and treatment of major depression.* UCLA Psychiatry resident didactic series in neurobiology. 2013
- Death and Rebirth: Insights from analysis of transcriptional time-series data.* Neurobehavioral Genetics Affinity Seminar. UCLA Brain Research Institute (BRI). 2012
- Diagnosing and managing headache in the elderly psychiatric population.* Advanced Geriatric Psychiatry Seminar UCLA 2012
- Wnt1 network analysis implicates canonical signaling in progranulin mediated frontotemporal dementia.* International Wnt signaling meeting 2011 (Los Angeles)
- The Evolving Interface Between Neuropsychiatry and Basic Neuroscience (Course leader NS211);* David Geffen School of Medicine UCLA 2010
- Dementia and the role of Wnt signaling.* BRI UCLA 2010
- Management strategies for neuropsychiatric disease* Advanced Geriatric Psychiatry Seminar UCLA 2010
- Wexler E**, Rosen E, Geschwind D. Altered canonical Wnt signaling implicated in progranulin-mediated frontotemporal dementia 2010 Neuroscience Meeting Planner San Diego, CA Society for Neuroscience; 2010.
- Rosen E, **Wexler E**, Versano R, Coppola G, Gao F, Oldham M, et al. Wnt signaling - Altered in PGRN mediated neuronal death and FTD 2010 Neuroscience Meeting Planner San Diego, CA Society for Neuroscience; 2010.
- Konopka G, **Wexler E**, Rosen E, Chen L, Osborn G, Lu D, et al. Modeling the functional genomics of autism using human neurons 2010 Neuroscience Meeting Planner San Diego, CA Society for Neuroscience; 2010.
- Prescription Usage For Treatment Of Irritability, Perseverative Behaviors, And Chorea. Mark Groves, M.D., Erik van Duijn, M.D., David Craufurd, M.D., Karen Anderson, M.D., Mark Guttman, M.D., **Eric Wexler**, M.D., Ph.D., Susan Perlman, M.D., Adam Rosenblatt, M.D., Dan van Kammen, M.D., Joe Giuliano, Jean-Marc Burgunder, M.D. LaVonne Goodman, M.D. Huntington's Disease. European Huntington's Dis-ease Network Meeting (Pargue) J Neurol Neurosurg Psychiatry September 2010 Vol 81 Suppl 1 pA43
- The Evolving Interface Between Neuropsychiatry and Basic Neuroscience (Course leader NS211);* David Geffen School of Medicine UCLA 2009
- Atypical dementias:* Advanced Geriatric Psychiatry Seminar UCLA 2009
- Delphi process for the development of consensus treatment guidelines for Huntington's disease Mark Groves, M.D., Erik van Duijn, M.D., David Craufurd, M.D., Karen Anderson, M.D., Mark Guttman, M.D., **Eric Wexler**, M.D., Ph.D, Susan Perlman, M.D., Adam Rosenblatt, M.D., Dan van Kammen, M.D., Joe Giuliano, Jean-Marc Burgunder, M.D. LaVonne Goodman, M.D. (HD World Congress, Vancouver, B.C. 2009)

Managing inherited neuropsychiatric disease Advanced Geriatric Psychiatry Seminar UCLA 2008

Early and rapid-onset dementias: Advanced Geriatric Psychiatry Seminar series UCLA 2007

Psychiatric manifestations Huntington's Disease and related disorders: Current and future strategies for treatment Combined UCLA Departments of Neurology and Neurosurgery, Neuroscience Grand Rounds, November 10, 2007

Neuropsychiatric Aspects of Huntington's Disease: Neuropsychiatric Institute Grand Rounds October 30, 2007, Los Angeles CA

Mood Stabilizers and Neurogenesis: Mental Retardation Research Center Symposium. 2007 Lake Arrowhead, CA

Diverse Autocrine/Paracrine Wnt Signals Modulate Adult Neurogenesis, **EM Wexler**, TD Palmer, & DH Geschwind Society for Neuroscience 2007, San Diego CA

Coppola G, Engelhardt M, Suberlak MN, **Wexler EM**, Santos M, Pandolfo M, et al. Functional genomic analysis of Friedreich's ataxia pathogenesis in vivo and in vitro. *Neurology*. 2007;68(12):A80-A

Coppola G, Engelhardt M, Suberlak MN, **Wexler EM**, Santos M, Miranda CJ, et al. Functional genomic analysis of Friedreich's ataxia pathogenesis in vivo and in vitro. *Annals of Neurology*. 2007;62:S24-S.

Chandler, M.L. & Pang, Iok-Hou & Doshi, Rupa & **Wexler, E.M.** & Walters, R.J. & Nawy, Scott & Desantis, L. & Kapin, M.A.. (1997). In vitro and in vivo protective effects of eliprodil in the retina [ARVO Abstracts] Investigative Ophthalmology and Visual Science. 38 (4). S147.

Pang IH, **Wexler EM**, Walters RJ, Reyes M, Reyes A, Shade DL, et al. Protective effects of eliprodil in retinal and neuronal cells and tissues. *Society for Neuroscience Abstracts*. 1996;22(1-3):1279.

Berkovich O, **Wexler E**, Nawy S. BDNF promotes survival of cultured retinal bipolar cells via a multi-receptor pathway. *Society for Neuroscience Abstracts*. 1996;22(1-3):998.

Wexler E, Stanton PK, Nawy S. Multiple kinases differentially modulate GABAergic conductances in cultured retinal neurons. *Society for Neuroscience Abstracts*. 1995;21(1-3):1840.

Wexler EM, Stanton PK. Prior synaptic activity enhances the induction of long-term depression (LTD) in hippocampus. *Society for Neuroscience Abstracts*. 1992;18(1-2):1351.

Wexler E, Kava R, West DB, Vonderporten A, Greenwood MRC. Effects of high-fat and sucrose diets on glucose-tolerance of obese wistar fatty and zucker fatty rats. *Faseb Journal*. 1988;2(5):A1222-A.

Editorial & Review Service:

Program and seminar reviewer: American Society of Clinical Psychopharmacology 2022-present

Research & Development grant reviewer; Neurobiology Panel, Department of Veterans Affairs 2012-17

Ad Hoc reviewer for *Cell*, *Cerebral Cortex*, *Neuron*, *Journal of Geriatric Psychiatry*, *Molecular & Cellular Neuroscience*, *Biological Psychiatry*, *Neurobiology of Disease*, *Clinical Psychiatry*, and *Stem Cells* 2002-2016:

PUBLICATIONS

Quoted in One Surprising Psychosis Treatment That Works: Learning to Live With the Voices. Julie Wernau. *Wall Street Journal* Dec. 21, 2024 [Front page and full page A10, describes successes at *California OnTrack*]

Burch, Jane; **Wexler, Eric**. What are the benefits and harms of aripiprazole compared with other atypical antipsychotics in people with schizophrenia? *Cochrane Clinical Answers*, 2017. <https://doi.org/10.1002/cca.496>

Burch, Jane; **Wexler, Eric**, How do second-generation antipsychotics compare with antidepressants for improving outcomes in people with unipolar major depressive disorder? *Cochrane Clinical Answers*, 2016 <https://doi.org/10.1002/cca.1194>

Natasha W. Hanners, Jennifer L. Eitson, Noriyoshi Usui, R. Blake Richardson, **Eric M. Wexler**, Genevieve Konopka, John W. Schoggins. Western Zika Virus in Human Fetal Neural Progenitors Persists Long Term with Partial Cytopathic and Limited Immunogenic Effects. *Cell Reports* 2016, Volume 15 , Issue 11 , 2315 – 2322

Burch, Jane; **Wexler, Eric**, In people with acute mania, how does aripiprazole affect outcomes? *Cochrane Clinical Answers*, 2015. <https://doi.org/10.1002/cca.682>

Tova F. Fuller, Roel A. Ophoff,, Chaochao Cai, Peter Langfelder, Stanley T. Parish, **Eric M. Wexler**, Dan Geschwind, Gil Atzmon,, Nir Barzilai,, Aviv Bergman, Leonard H. van den Berg, Giovanni Coppola, Rita B. Effros,, Steve Horvath, Genes and pathways mediating human aging (in preparation)

Wexler E., Lu D., Mathews E, Gao F., Coppola G., and Geschwind D.H Mood stabilizers lithium and valproic acid activate complementary neurodevelopmental programs. (in preparation)

Jason L. Stein, Luis de la Torre-Ubieta, Yuan Tian1, Neelroop N. Parikshak, Dylan K. Baker, Daning Lu, Jennifer K. Lowe, **Eric M. Wexler**, Daniel H. Geschwind A quantitative framework to evaluate modeling of cortical development by neural stem cells *Neuron*. 2014 Jul 2;83(1):69-86

Burch, Jane; **Wexler, Eric**, In people with major depression, how does agomelatine compare with other antidepressive agents at improving outcomes? *Cochrane Clinical Answers*. 2014. <https://doi.org/10.1002/cca.499>

Eric Wexler Clinical neurogenetics: behavioral management of inherited neurodegenerative disease. *Neurol Clin*. 2013 Nov;31(4):1121-44.

Fogel BL, **Wexler E**, Wahnich A, Friedrich T, Vijayendran C, Gao F, Parikshak N, Konopka G, Geschwind DH. RBFOX1 Regulates Both Splicing and Transcriptional Networks in Human Neuronal Development. *Hum. Mol. Genetics*. 2012 Oct 1;21(19):4171-86

Konopka G, **Wexler E**, Rosen E, Mukamel Z, Osborn GE, Chen L, et al. Modeling the functional genomics of autism using human neurons. [Cover Article] *Mol Psychiatry*, 2012 Feb;17(2):202-14

EM Wexler and DH Geschwind DISC1: a schizophrenia gene with multiple personalities. *Neuron* 2011 Nov 17;72(4):501-3.

Eric M Wexler and Brent Fogel (2011) Psychosis in Spinocerebellar Ataxia Type 10. *Am J Psychiatry*. 2011 Dec 1;168(12):1339-40

Wexler EM, Rosen E, Lu D, Osborn GE, Martin E, Raybould H, et al. Genome-wide analysis of a wnt1-regulated transcriptional network implicates neurodegenerative pathways. *Science Signal*. 2011;4(193):ra65.

Rosen EY, **Wexler EM**, Versano R, Coppola G, Gao F, Winden KD, et al. Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating wnt signaling. *Neuron*. 2011;71(6):1030-42.

E.M. Wexler (2011) Cell based therapies - gene therapy/stem cell therapy in the future for degenerative disorders in Principles and Practice of Geriatric Psychiatry 3e, Wiley-Blackwell.

Nakano I, Joshi K, Visnyei K, Hu B, Watanabe M, Lam D, **Wexler E**, Saigusa K, Nakamura Y, Laks DR, Mischel PS, Viapiano M, Kornblum HI Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway. *Neuro Oncol*. 2011;13(6):622-34.

Mukamel Z, Konopka G, **Wexler E**, Osborn GE, Dong H, Bergman MY, et al. Regulation of MET by FOXP2, Genes Implicated in Higher Cognitive Dysfunction and Autism Risk. *J Neurosci*. 2011;31(32): 11437-42.

Wexler EM, Paucer A, Kornblum HI, Palmer TD, Geschwind DH. Endogenous Wnt signaling maintains neural progenitor cell potency. *Stem Cells*. 2009;27(5):1130-41.

Wexler EM, Geschwind DH, Palmer TD. Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. [Cover Article] *Mol Psychiatry*. 2008;13(3):285-92.

Wexler E. Markers of adult neural stem cells. *Methods Mol Biol.* 2008;438:243-68.

Wexler EM, Geschwind DH. Out FOXing Parkinson disease: where development meets neurodegeneration. *PLoS Biol.* 2007;5(12):e334. PMID: 2140089.

Coppola G, Choi SH, Santos MM, Miranda CJ, Tentler D, **Wexler EM**, et al. Gene expression profiling in frataxin deficient mice: microarray evidence for significant expression changes without detectable neurodegeneration. *Neurobiol Dis.* 2006;22(2):302-11.

Dougherty JD, Garcia AD, Nakano I, Livingstone M, Norris B, Polakiewicz R, **Wexler EM**, Sofroniew MV, Kornblum HI, Geschwind DH. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase. *J. Neurosci.* 2005;25(46):10773.

Wexler E, Palmer T. Where, oh where, have my stem cells gone? *Trends Neurosci.* 2002;25(5):225-7.

Pang IH, **Wexler EM**, Nawy S, DeSantis L, Kapin MA. Protection by eliprodil against excitotoxicity in cultured rat retinal ganglion cells. *Investigative Ophthalmology & Visual Science.* 1999;40(6):1170.

Wexler EM, Stanton PK, Nawy S. Nitric oxide depresses GABA_A receptor function via coactivation of cGMP-dependent kinase and phosphodiesterase. *Journal of Neuroscience.* 1998;18(7):2342.

Wexler EM, Berkovich O, Nawy S. Role of the low-affinity NGF receptor (p75) in survival of retinal bipolar cells. *Visual Neuroscience.* 1998;15(2):211.

E.M. Wexler *Development and Electrophysiology of Cultured Mammalian Retinal Interneurons [focus on GABA_A mediation signaling].* (1998). Doctoral Thesis

Stanton PK, **Wexler EM**, Velisek L, Hedberg T. Long-Term Depression Of Synaptic Transmission: Cellular Mechanisms And Regulation By Previous Synaptic History. In: Baudry M, Davis JL, editors. Long-term potentiation, volume 2. Cambridge, Mass.: MIT Press; 1994. p. 169-86.

Wexler EM, Stanton PK. Priming of homosynaptic long-term depression in hippocampus by previous synaptic activity. *Neuroreport.* 1993;4(5):591.

E. Wexler and S. Singer (1990). Physician Heal Thy Science & Rebuttal. AMSA Journal Fall pp.21-23

FORENSIC SERVICES (Recent Cases of Note)

People of California v. Zainali Jaffer. (Helped mount a successful automatism defense) Mr. Jaffer was the CEO of a Silicon Valley start-up valued at over \$500 million when an episode of bizarre behavior led to multiple charges of sexual assault, battery on his father and a police officers and felony child abuse. This case was widely covered in the press with the San Mateo DA going on network television declaring it a case of such obvious guilt it didn't even require investigation. I was retained by Patrick Clancy of *The Innocence Team* to assess his mental state at the time of offense. My analysis revealed convincing evidence that he was not intoxicated with LSD, as asserted by the prosecution. Instead, he was initially unconscious, and later insane, due to the effects of an undiagnosed bipolar disorder that was exacerbated by prescribed anti-inflammatory and anti-histaminic medications. Substantiating the unconsciousness defense was critical since it is an affirmative defense against many of the crimes he was charged with that do not require specific intent. Ultimately, all criminal charges were dropped in July 2018 with the district attorney's office definitively stating that no crimes were committed, not merely stating there was insufficient evidence to prosecute.

Reagents of the University of California: Los Angeles Medical Center v. United Behavioral Health

Reagents of the University of California: Los Angeles Medical Center v. Magellan-Blue Shield of California

Reagents of the University of California: Los Angeles Medical Center v. Blue Cross of California.

Reagents of the University of California: Irvine Medical Center v. United Behavioral Health

Reagents of the University of California: Irvine Medical Center v. Magellan-Blue Shield of California

Alameda Medical Center v. United Behavioral Health

I am regularly retained by counsel to the Reagents of California, UCLA Healthcare and UCI healthcare systems in their attempt to obtain just compensation for psychiatric care that was provided in good faith. I have testified numerous times and opined on more than one hundred cases regarding issues of medical necessity and appropriate level of care.

Tolerico v. State of California, Department of Transportation. Retained by defense counsel (State of California) in case of former police officer who suffered a traumatic brain injury due to reckless off-duty behavior.

Yessica Gonzalez v City of Montclair. I was retained by defense counsel (City of Montclair California) as a consulting expert to review the tens of thousands of pages of medical records in this complex traumatic brain injury case. Herein, I advised the California Dept. of Transportation in a highly complex case of catastrophic brain injury that involved intervening neuropharmacologic issues and pre-existing psychopathology

Orexo v. Sun Pharma. I was retained by counsel at Winston & Strawn to assist in defense against claims of patent infringement, in connection with Sun's ANDA application for a generic buprenorphine/naloxone tablet, a narcotic used in the treatment of opiate addiction. I provided analysis and testimony as part of Sun's obviousness defense, specifically refuting unfounded claims of clinical secondary considerations and opining a lack of nexus to the original patents.

Hausman v. McDermott, Will & Emery LLP. I was retained by defense counsel O'Melveny & Meyers LLP to provide expertise on the interplay between psychological stressors and function impairment among sufferers of multiple sclerosis. This case favorably settled in 2018

People of Nevada v. Mane Shah. Dr. Shah was indicted on two counts of sexual assault and gross or lewd behavior. I was retained by Chesnoff & Schonfeld for my expertise in complex neuropharmacology and physiology. Specific issues involved opiate vs. sedative/hypnotic induced delirium, withdrawal and sleep disturbances. I developed evidence of significant inconsistencies in the alleged victim's narrative and a more medically reasonable explanation for her misperceptions. The case resolved in 2018 mid-trial with a last-minute offer by the DA that allowed Dr. Shah to continue practicing medicine without restriction or sanction, in exchange for accepting probation.

Charles Dion (and others similarly situated) v. Kaiser Health Foundation. Gianelli & Morris represented the class of patients who were insured by Kaiser, but were denied the benefits of residential psychiatric treatment. I was retained by plaintiff for my expertise in inpatient and transitional outpatient psychiatric care standards. This case favorably settled in 2018

SCH v. Goodman, M.D. Asked to opine on standard of inpatient care.

Keydata: I was engaged by the British Government's Financial Conduct Authority (equivalent to the S.E.C) to evaluate the testamentary capacity of a principal figure in the largest financial fraud case in post-war Britain.

Hose v Seacrest. Retained to opine on standard of care in geriatric psychiatry setting

Omar Nagy v. Bank of Nevada. I was retained by defense counsel Ogletree & Deakins as a consulting expert to evaluate the reasonableness of the plaintiff's psychiatric FMLA claim. This case resolved with summary judgment for the defendant.

Andrews v. Alameda County Sheriff's Department: Claims wrongful death after deputies failed to recognize psychogenic polydipsia in known schizophrenic detainee.

Peak v Frisen-Peak: Opined and testified at trial on need for bipolar medication management as part of a custody determination.

Parkinson v Parkinson: Retained by petitioner's counsel to evaluate respondent's mental health and capacity for child safety.

Weivoda v Weivoda: Retained by respondent's counsel to evaluate petitioner's mental health and capacity for child safety.

Sobel v Los Robles Hospital: Claims negligent care allowed schizophrenic patient to attempt suicide by jumping off overpass

Atterbury v Babus: Claimed negligence prescribing of sedative led to addiction and permanent harm

State of Tennessee v. David Lynn Jordan. This is a death penalty appeal where the Office of the Federal Public Defender retained me to assess whether the convicted' psychiatric illness might mitigate his sentence.

Gould (Cooper) v. Anwar (St Joseph's Hospital): Claims negligence and wrongful death after patient committed suicide by hanging while on a locked and monitored psychiatric unit.

Eberle v. Crossroads: Retained by plaintiff's counsel to evaluate standard of care, and claims of wrongful death due to opiate overdose while at rehab facility

McCluer v Lowry: claims negligence in diagnosis of bipolar disorders and subsequent treatment contributed to untimely death.

Andrews v Alameda County: Claim of wrongful death while in jail due to a failure to recognize the medical complications arising from his underlying psychotic disorder.

Chenevert v Spivak: Evaluated claim of emotional distress secondary to negligently executed plastic surgery

Rudolph v Wilson: case issues revolve around capacity for informed consent in patients suffering from schizophrenia spectrum illnesses

Ulrich v Sutter Valley Hospitals: Claims negligent care of suicidal schizoaffective patient allowed him to be improperly discharged and subsequently jump off the roof of the hospital's garage.

Patel v. Alameda Health Systems: claims negligence failed to recognize frontal lobe hemorrhage leading to permanent severe cognitive impairment

Garcia v Vasquez: Evaluated plaintiff who was claiming cognitive and emotional injury following a motor vehicle accident

Davison v Orchard Pointe: Level of care and wrongful death of Alzheimer's patient in senior living

Griffiths v CPIC. Claim of traumatic brain injury and posttraumatic stress disorder after a low speed motor vehicle accident

Kopmar v Pacas: Evaluated claim of posttraumatic stress disorder (PTSD) and emotional distress following a motor vehicle accident

Jahanpanah v. Klein: Evaluated plaintiff in claim of posttraumatic stress disorder (PTSD) and emotional distress following a motor vehicle accident

Sherafati v. Odriscoll: evaluated claim of posttraumatic stress disorder (PTSD) and emotional distress following a motor vehicle accident

Gamm v Lloyds of London: Evaluated claim of complete psychiatric disability due to a motor vehicle accident

Volante-Kromer Vs. Kromer: evaluation of medical records with respect to the question of testamentary capacity.

Adams v. Normis. Evaluated plaintiff for complaints of trauma and emotional distress following a motor vehicle accident.

California v Karen: Obtained mental health diversion under PC1001.36

California v Jagodowicz: Obtained mental health diversion under PC1001.36

California v Smith. Defendant was originally deemed not competent to stand trial. After regaining the capacity to assist in his own defense I assisted with instatement of conservatorship. I later assisted foreign counsel in Great Britain with having his panoply of minor felony charges dismissed and the individual repatriated to California.

Conservatorship: I have assisted in obtaining either LPS or Probate conservatorships for dozens of patients

Pada v. Radnet: Rendered opinion on appropriateness of psychiatric treatment and reasonable accommodations for individual with concomitant epilepsy and generalized anxiety disorder

Wilson v Teledoc: Evaluated standard of care in patient who develop psychosis after being prescribed antidepressants

Rose v. Outback Care Group: Evaluated claim of psychiatric patient treated under improper level of care leading to wrongful death

Cammad Inc., et al. v. Dionysus Investors. Claims of stress induced incapacity

Caggiano v. Amis: evaluated claimed tardive dyskinesia due to improper prescribing of antipsychotic medications to patient with genetic disorder

Elizabeth Taylor v. Alkiviades David; Karl Zirpel vs. Alki David Productions: Retained by counsels to evaluate defendant for sequelae of traumatic brain injury and manifest psychosis, and to recommend treatment to mitigate defendant's interference with his own defense.

Deposition testimony in past 10 years

Barbara Gould (Est. Leonard Cooper) v. Syed Anwar, M.D.
Elizabeth Taylor vs. Alkiviades David
Berndtson, Angela vs. Park Place Village
Blaylock, Karen vs. State of California, Department of Motor Vehicles
Natalya Blindman v UCLA
Brown, Kina vs. Department of Social Services
Chavez, Ana vs. Palmdale Regional Medical Center
Eberle vs. Crossroads
Espejo, Miguel vs. Quest Diagnostics
Flores, Jose vs. All Around, Inc.,
Frias, Evangelina Vs Waterway Plastics
Gentle, Robby vs. Parking Concepts Inc.
Jones, Rodger vs. County of Ventura
Martinez, Filomeno vs. Oxnard Union High School District
Mateo, Honoria vs. Labcorp
Orexio v Sun Pharma
Olivares, Martha vs. Whole Foods Market
Ortiz, Leonardo vs. Progressive Environmental Industries
Ortega Vanessa vs. Bank of America
Pada vs Radnet
Poehler, Glenda vs. Guernsey Coating Laboratories
Preston, Gwenette vs Antelope Valley Community College District
Rayas, Jacqueline vs. Harbor Freight Tools
Rodriguez, Alfredo vs. Sa Recycling
Peak v. Friesen-Peak
Reagents of the University of California vs. United Behavioral Health (aggregated)
Reagents of the University of California vs. Blue Shield of California (aggregated)
Reagents of the University of California vs. Blue Cross of California (aggregated)
Vasquez, Manuel vs. Sun Hill Properties, Inc.
Timothy Wells vs. Southern California Gas Company
Sharon West vs. Vons Companies Inc.
Yancey, Carmelia vs. Lowe's Home Centers
Yun, Harry vs. Costco
Keisha Zapeda v LAUSD

Nourollah Zaghi v State Of California

Zavaleta, Samuel vs. Conifer Value Based Care, Llc.

Zhang, Zhan vs. Hokkaido Seafood Buffet